Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for diseases with unmet medical need, focusing on cardiovascular indications. Its commercial product is ARCALYST, an IL-1α and IL-1β cytokine trap approved in the United States for recurrent pericarditis, CAPS and DIRA. Kiniksa markets and distributes ARCALYST in the United States through a network of specialty pharmacies and a specialty salesforce, and shares profits on U.S. sales and third-party proceeds with Regeneron. It has granted Huadong exclusive rights to develop and commercialize ARCALYST in a defined territory. Kiniksa’s product candidates include KPL-387, in clinical development for recurrent pericarditis, and preclinical KPL-1161, both targeting IL-1R1. Abiprubart, an investigational antibody targeting the CD40-CD154 interaction, is another asset; the company plans to discontinue its development in Sjögren’s Disease and explore strategic alternatives. Kiniksa also conducts internal discovery activities and relies on third parties for much of its manufacturing.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Kiniksa Pharmaceuticals (KNSA) CEO Sanj Patel sold 151,300 shares for $14.3M at $94.71 each under a 10b5-1 plan, after exercising 145,763 options at $17.92. Patel now holds 774,500 shares indirectly. The sale was part of a pre-agreed trading plan.
Patel Sanj K (CHAIRMAN & CEO) sold 151,300 indirectly-held shares of Kiniksa Pharmaceuticals International, plc (KNSA) at an average of $94.71 ($92.35–$96.05, $14.33M total) across 5 trades on 2026-11-04 under a Rule 10b5-1 trading plan.
Patel Sanj K (CHAIRMAN & CEO) sold 402,494 indirectly-held shares of Kiniksa Pharmaceuticals International, plc (KNSA) at an average of $92.92 ($90.77–$98.16, $37.40M total) across 15 trades over 2026-10-30 to 2026-11-03 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning KNSA (Kiniksa Pharmaceuticals International, plc). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent KNSA coverage spans insider activity and financial news.
In the last 30 days, KNSA insiders filed 52 SEC Form 4 transactions — no purchases and 52 sales ($77.1M). The most active reporter was Patel Sanj K, CHAIRMAN & CEO, with 20 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Large insider sale may signal reduced confidence or liquidity need, likely pressuring the stock.
Significant insider sell may signal confidence concerns, likely putting downward pressure on the stock.
Large insider sale may signal reduced confidence and could pressure the stock price.
The insider sale may create modest selling pressure on KNSA.
The insider sale may signal reduced confidence or simply portfolio rebalancing, potentially pressuring the stock.
AlphAI scores every news story that mentions KNSA with an AI model for sentiment and relevance, and aggregates insider trades from Kiniksa Pharmaceuticals International, plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Kiniksa Pharmaceuticals (KNSA) CEO Sanj Patel sold 151,300 shares for $14.3M at $94.71 each under a 10b5-1 plan, after exercising 145,763 options at $17.92. Patel now holds 774,500 shares indirectly. The sale was part of a pre-agreed trading plan.
Patel Sanj K (CHAIRMAN & CEO) sold 151,300 indirectly-held shares of Kiniksa Pharmaceuticals International, plc (KNSA) at an average of $94.71 ($92.35–$96.05, $14.33M total) across 5 trades on 2026-11-04 under a Rule 10b5-1 trading plan.
Patel Sanj K (CHAIRMAN & CEO) sold 402,494 indirectly-held shares of Kiniksa Pharmaceuticals International, plc (KNSA) at an average of $92.92 ($90.77–$98.16, $37.40M total) across 15 trades over 2026-10-30 to 2026-11-03 under a Rule 10b5-1 trading plan.
Ragosa Mark (CHIEF FINANCIAL OFFICER) sold 36,783 shares of Kiniksa Pharmaceuticals International, plc (KNSA) at an average of $92.16 ($91.40–$94.01, $3.39M total) across 4 trades on 2026-11-02 under a Rule 10b5-1 trading plan.
Paolini John F. (CHIEF MEDICAL OFFICER) sold 96,000 shares of Kiniksa Pharmaceuticals International, plc (KNSA) at an average of $93.09 ($92.02–$97.77, $8.94M total) across 10 trades over 2026-10-30 to 2026-11-02 under a Rule 10b5-1 trading plan.
Moat Ross (CHIEF OPERATING OFFICER) sold 103,585 shares of Kiniksa Pharmaceuticals International, plc (KNSA) at an average of $92.93 ($91.23–$97.76, $9.63M total) across 11 trades over 2026-10-30 to 2026-11-02 under a Rule 10b5-1 trading plan.
Megna Michael R (CHIEF ACCOUNTING OFFICER) sold 36,260 shares of Kiniksa Pharmaceuticals International, plc (KNSA) at an average of $94.43 ($91.87–$97.74, $3.42M total) across 7 trades on 2026-10-30 under a Rule 10b5-1 trading plan.
JP Morgan reaffirmed its Overweight rating on Kiniksa Pharmaceuticals and increased its price target to $122 from $107, citing a 32.3% upside from the last close of $92.24. Other recent analyst targets for the company range from $101 to $110.
Kiniksa Pharmaceuticals (KNSA) shares rose 120% year-to-date, driven by strong sales of lead drug ARCALYST. Q1 2026 revenue was $214.3M, up 56% YoY. The company raised 2026 sales guidance to $1.045B-$1.050B, targeting blockbuster status. KNSA's stock reached an all-time high of $98.36.
Wedbush kept its Outperform rating on Kiniksa Pharmaceuticals, setting a $102 price target, suggesting a 14.3% upside from the Oct 27 close of $89.20. The firm cited strong Q3 revenue growth for Arcalyst, up 17.4% quarter-over-quarter and 58.1% year-over-year, and expanding market potential.
